[go: up one dir, main page]

MX2018003929A - TETRAHIDRO-1H-PIRIDO ANTI-STROGEN DRUGS [3,4-B] INDOL. - Google Patents

TETRAHIDRO-1H-PIRIDO ANTI-STROGEN DRUGS [3,4-B] INDOL.

Info

Publication number
MX2018003929A
MX2018003929A MX2018003929A MX2018003929A MX2018003929A MX 2018003929 A MX2018003929 A MX 2018003929A MX 2018003929 A MX2018003929 A MX 2018003929A MX 2018003929 A MX2018003929 A MX 2018003929A MX 2018003929 A MX2018003929 A MX 2018003929A
Authority
MX
Mexico
Prior art keywords
tetrahidro
strogen
pirido
indol
drugs
Prior art date
Application number
MX2018003929A
Other languages
Spanish (es)
Other versions
MX382269B (en
Inventor
C Myles David
J Kushner Peter
L Harmon Cyrus
Original Assignee
Olema Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olema Pharmaceuticals Inc filed Critical Olema Pharmaceuticals Inc
Publication of MX2018003929A publication Critical patent/MX2018003929A/en
Publication of MX382269B publication Critical patent/MX382269B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
MX2018003929A 2015-10-01 2016-09-29 ANTI-ESTROGENIC DRUGS TETRAHYDRO-1H-PYRIDE [3,4-b] INDOL. MX382269B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562235900P 2015-10-01 2015-10-01
PCT/US2016/054549 WO2017059139A1 (en) 2015-10-01 2016-09-29 TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS

Publications (2)

Publication Number Publication Date
MX2018003929A true MX2018003929A (en) 2018-11-22
MX382269B MX382269B (en) 2025-03-13

Family

ID=58427985

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018003929A MX382269B (en) 2015-10-01 2016-09-29 ANTI-ESTROGENIC DRUGS TETRAHYDRO-1H-PYRIDE [3,4-b] INDOL.
MX2021005214A MX2021005214A (en) 2015-10-01 2018-03-28 TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021005214A MX2021005214A (en) 2015-10-01 2018-03-28 TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS.

Country Status (26)

Country Link
US (5) US10292971B2 (en)
EP (2) EP3912680A1 (en)
JP (3) JP6776348B2 (en)
KR (2) KR102710603B1 (en)
CN (2) CN113248494A (en)
AU (4) AU2016331065B2 (en)
BR (2) BR122023020677A2 (en)
CA (1) CA3000410A1 (en)
CL (1) CL2018000827A1 (en)
CY (1) CY1124669T1 (en)
DK (1) DK3355884T3 (en)
ES (1) ES2881398T3 (en)
HR (1) HRP20211124T1 (en)
HU (1) HUE055321T2 (en)
IL (3) IL310489A (en)
LT (1) LT3355884T (en)
MX (2) MX382269B (en)
NZ (1) NZ779654A (en)
PL (1) PL3355884T3 (en)
PT (1) PT3355884T (en)
RS (1) RS62133B1 (en)
RU (2) RU2745742C1 (en)
SI (1) SI3355884T1 (en)
SM (1) SMT202100433T1 (en)
UA (1) UA122346C2 (en)
WO (1) WO2017059139A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112375077A (en) 2014-12-18 2021-02-19 豪夫迈·罗氏有限公司 Tetrahydro-pyrido [3,4-b ] indole estrogen receptor modulators and uses thereof
CN113248494A (en) * 2015-10-01 2021-08-13 奥列马制药公司 tetrahydro-1H-pyridine [3,4-b ] indole antiestrogens
US20170166551A1 (en) 2015-12-09 2017-06-15 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulator compounds
CA3012078C (en) * 2016-02-05 2024-01-30 Inventisbio Inc. Selective estrogen receptor degraders and uses thereof
US10125135B2 (en) 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
US10149839B2 (en) 2016-07-25 2018-12-11 Astrazeneca Ab Chemical compounds
WO2018049042A1 (en) * 2016-09-07 2018-03-15 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancers by inhibiting estrogen signaling in myeloid-derived suppressor cells
PL3640251T3 (en) 2016-10-24 2022-04-11 Astrazeneca Ab 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
MX2019008158A (en) 2017-01-06 2019-12-09 G1 Therapeutics Inc Combination therapy for the treatment of cancer.
MY196317A (en) 2017-01-30 2023-03-24 Astrazeneca Ab Estrogen Receptor Modulators
KR20190117582A (en) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. Benzothiophene Estrogen Receptor Modulator
WO2019192533A1 (en) * 2018-04-04 2019-10-10 深圳福沃药业有限公司 Estrogen receptor degrading agent for treating breast cancer
US20190375732A1 (en) 2018-05-14 2019-12-12 David Hung Anti-cancer nuclear hormone receptor-targeting compounds
IL278063B2 (en) 2018-06-21 2025-08-01 Hoffmann La Roche Solid forms of 3-((r3,r1)-1-(6,2-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-9,4,3,1-tetrahydro-h2-pyrido[4,3-b]indol-2-yl]2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds containing a substituted phenyl or pyridinyl residue, including methods for using them
AU2018454987B2 (en) * 2018-12-24 2025-05-29 InventisBio Co., Ltd. Novel salts of selective estrogen receptor degraders
JP2022532342A (en) * 2019-05-14 2022-07-14 ニューベイション・バイオ・インコーポレイテッド Anti-cancer nuclear hormone receptor targeting compound
AU2020311337A1 (en) * 2019-07-07 2022-01-20 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
WO2021097046A1 (en) 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
KR20220151616A (en) 2020-03-06 2022-11-15 올레마 파마슈티컬스 인코포레이티드 Methods of treating estrogen receptor-related diseases
IL297218A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Pharmaceutical formulations
WO2021214253A1 (en) 2020-04-24 2021-10-28 Astrazeneca Ab Dosage regimen for the treatment of cancer
US11848549B2 (en) * 2020-09-15 2023-12-19 Easy Solar Products, Inc. Junction box with flashing for a tile surface
JP2024502270A (en) 2020-12-23 2024-01-18 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Estrogen receptor modulators
CN116744920A (en) * 2021-02-08 2023-09-12 贝达药业股份有限公司 Heteroarylpiperidine derivatives and pharmaceutical compositions and applications thereof
WO2022235585A1 (en) 2021-05-03 2022-11-10 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CA3226156A1 (en) * 2021-07-08 2023-01-12 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2023091550A1 (en) * 2021-11-18 2023-05-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2023221122A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
KR20250068623A (en) 2022-08-11 2025-05-16 이벡스타 바이오 Compounds for cancer treatment
CA3262231A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
CA3261772A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
AU2023324856A1 (en) 2022-08-19 2025-01-30 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
AU2023356291A1 (en) * 2022-10-05 2025-04-17 Novartis Ag Methods of treating estrogen receptor-mediated disorders
WO2024076633A1 (en) * 2022-10-05 2024-04-11 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
AU2023390702A1 (en) * 2022-12-09 2025-06-12 Olema Pharmaceuticals, Inc. Dosage forms of an estrogen receptor antagonist
WO2025106890A1 (en) * 2023-11-17 2025-05-22 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2025168601A1 (en) 2024-02-05 2025-08-14 Evexta Bio Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases
WO2025175249A1 (en) 2024-02-14 2025-08-21 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
DE69531476T2 (en) * 1994-09-12 2004-06-09 Lilly Industries Ltd., Basingstoke Serotonergic modulators
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
ID24568A (en) 1997-11-06 2000-07-27 American Home Prod ORAL CONTRACEPTION THAT CONTAINS ANTI-ESTROGEN PLUS PROGESTIN
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
US6583170B1 (en) 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CO5271697A1 (en) 2000-01-12 2003-04-30 Pfizer Prod Inc COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF AFFECTIONS THAT RESPOND TO AN INCREASE OF TESTOSTERONE
CO5271709A1 (en) 2000-01-12 2003-04-30 Pfizer Prod Inc COMPOSITIONS AND PROCEDURES FOR THE AND TREATMENT OF AFFECTIONS RESPONDING TO STROGENS
CO5271696A1 (en) 2000-01-12 2003-04-30 Pfizer Prod Inc PROCEDURE TO REDUCE MORBILITY AND RISK OF MORTALITY
CO5251465A1 (en) 2000-01-26 2003-02-28 Pfizer Prod Inc COMPOSITIONS AND PROCEDURES TO TREAT OSTEOPOROSIS AND REDUCE CHOLESTEROL
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
BR0112360A (en) 2000-07-06 2003-05-06 Wyeth Corp Method for Increasing Nitric Oxide Synthase Activity
AU2001271784A1 (en) 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
US20020016318A1 (en) 2000-07-06 2002-02-07 American Home Products Corporation Methods of treating breast disorders
CN1450913A (en) 2000-07-06 2003-10-22 惠氏公司 Combination use of bisphosphonates, estrogenic agents and optionally estrogens
WO2002003990A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
AU2001271781A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating sphincter incontinence
AU2001273144A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
WO2002003977A2 (en) 2000-07-06 2002-01-17 Wyeth Combinations of statins, estrogenic agents and optionally estrogens
EP1990051A1 (en) 2000-07-06 2008-11-12 Wyeth Combinations of SSRI and estrogenic agents
AR030064A1 (en) 2000-07-06 2003-08-13 Wyeth Corp METHODS TO INHIBIT THE UTEROTROPHIC EFFECTS OF ESTROGEN AGENTS
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
WO2002013802A2 (en) 2000-08-11 2002-02-21 Wyeth Method of treating estrogen receptor positive carcinoma
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
EP1417169A2 (en) 2001-08-11 2004-05-12 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
EP1720862A1 (en) 2004-02-03 2006-11-15 Eli Lilly And Company Kinase inhibitors
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
AU2005222632B2 (en) * 2004-03-15 2012-02-09 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
AU2006206446A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
RU58668U1 (en) 2006-06-05 2006-11-27 Открытое акционерное общество "Нижегородский машиностроительный завод" WATER BOILER
PL2434891T3 (en) 2009-05-27 2020-12-28 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
US20120157401A1 (en) 2009-05-27 2012-06-21 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
US20120202801A1 (en) 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
DK2580210T5 (en) 2010-06-10 2017-06-19 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND APPLICATIONS THEREOF
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
JP5886873B2 (en) * 2010-12-24 2016-03-16 メルク・シャープ・エンド・ドーム・ベー・フェー N-substituted azetidine derivatives
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
CA2857061A1 (en) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
JP6286031B2 (en) * 2013-05-28 2018-02-28 アストラゼネカ アクチボラグ Compound
JP6389517B2 (en) 2013-06-19 2018-09-12 セラゴン ファーマシューティカルズ， インク． Azetidine estrogen receptor modulator and use thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
JP6576916B2 (en) 2013-06-19 2019-09-18 セラゴン ファーマシューティカルズ， インク． Estrogen receptor modulators and uses thereof
RU2745668C2 (en) * 2014-10-23 2021-03-30 Ой Эм Ти Джи-Мелтрон Лтд Lighting device for explosive and fire hazardous areas
GB2567981B (en) * 2014-10-31 2019-10-30 Karsten Mfg Corp Grooves of golf club heads and methods to manufacture grooves of golf club heads
CN112375077A (en) 2014-12-18 2021-02-19 豪夫迈·罗氏有限公司 Tetrahydro-pyrido [3,4-b ] indole estrogen receptor modulators and uses thereof
EP3233818A1 (en) 2014-12-18 2017-10-25 F. Hoffmann-La Roche AG Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
CN113248494A (en) 2015-10-01 2021-08-13 奥列马制药公司 tetrahydro-1H-pyridine [3,4-b ] indole antiestrogens
US20170362228A1 (en) 2016-06-16 2017-12-21 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
PL3640251T3 (en) 2016-10-24 2022-04-11 Astrazeneca Ab 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
TWI702219B (en) 2018-07-12 2020-08-21 美商美國禮來大藥廠 Selective estrogen receptor degraders
SG11202100145YA (en) 2018-07-12 2021-02-25 Lilly Co Eli Selective estrogen receptor degraders

Also Published As

Publication number Publication date
US11229630B2 (en) 2022-01-25
EP3355884A4 (en) 2019-06-05
JP2018530549A (en) 2018-10-18
EP3912680A1 (en) 2021-11-24
JP2023087106A (en) 2023-06-22
PT3355884T (en) 2021-07-26
JP7650316B2 (en) 2025-03-24
US20210059991A1 (en) 2021-03-04
CL2018000827A1 (en) 2018-09-28
AU2021206861B2 (en) 2023-02-02
US10292971B2 (en) 2019-05-21
AU2023202620B2 (en) 2025-02-27
PL3355884T3 (en) 2021-11-29
RS62133B1 (en) 2021-08-31
NZ741130A (en) 2024-11-29
ES2881398T3 (en) 2021-11-29
RU2021107754A (en) 2021-04-01
SMT202100433T1 (en) 2021-09-14
BR112018006121B1 (en) 2024-01-23
JP6776348B2 (en) 2020-10-28
US10624878B2 (en) 2020-04-21
CN113248494A (en) 2021-08-13
CY1124669T1 (en) 2022-07-22
US20240131013A1 (en) 2024-04-25
AU2025203540A1 (en) 2025-06-05
MX2021005214A (en) 2021-06-18
UA122346C2 (en) 2020-10-26
MX382269B (en) 2025-03-13
US11672785B2 (en) 2023-06-13
AU2021206861A1 (en) 2021-08-12
EP3355884B1 (en) 2021-04-28
CN108366996A (en) 2018-08-03
IL286518B2 (en) 2024-06-01
LT3355884T (en) 2021-07-26
KR20180071274A (en) 2018-06-27
IL258363B (en) 2021-10-31
RU2745742C1 (en) 2021-03-31
KR20240142622A (en) 2024-09-30
HUE055321T2 (en) 2021-11-29
WO2017059139A1 (en) 2017-04-06
JP2021001231A (en) 2021-01-07
IL286518B1 (en) 2024-02-01
BR112018006121A2 (en) 2018-10-23
EP3355884A1 (en) 2018-08-08
US20220370421A1 (en) 2022-11-24
CN108366996B (en) 2021-04-09
KR102710603B1 (en) 2024-09-27
BR122023020677A2 (en) 2023-12-12
IL310489A (en) 2024-03-01
JP7277424B2 (en) 2023-05-19
HRP20211124T1 (en) 2021-10-15
DK3355884T3 (en) 2021-08-02
US20240226073A9 (en) 2024-07-11
IL258363A (en) 2018-05-31
AU2016331065B2 (en) 2021-04-29
US20190247372A1 (en) 2019-08-15
US20180289679A1 (en) 2018-10-11
SI3355884T1 (en) 2021-11-30
CA3000410A1 (en) 2017-04-06
AU2023202620A1 (en) 2023-05-18
IL286518A (en) 2021-10-31
NZ779654A (en) 2024-12-20
AU2016331065A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
MX2018003929A (en) TETRAHIDRO-1H-PIRIDO ANTI-STROGEN DRUGS [3,4-B] INDOL.
ZA202108745B (en) Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
ZA201800022B (en) Substituted heterocyclyl derivatives as cdk inhibitors
MA39986A (en) Purine derivatives as cd73 inhibitors for the treatment of cancer
IL269658B (en) Substituted indoline derivatives as dengue viral replication inhibitors
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
IL269657A (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12017501816A1 (en) Azabensimidazoles and their use as amp a receptor modulators
IL270726A (en) Substituted indoline derivatives as dengue viral replication inhibitors
SI3436437T1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
SI3630724T1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX2016009581A (en) 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use.
MX2016009621A (en) Furo-3-carboxamide derivatives and methods of use.
NZ730585A (en) Indolinone compounds and uses thereof
AU2017257755A1 (en) Benzoylglycine derivatives and methods of making and using same
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
MX2013008269A (en) Pharmaceutical composition comprising pyridone derivatives.
MX2018002487A (en) Pharmaceutical compositions comprising 3-(5-amino-2-methyl-4-oxo- 4h-quinazolin-3-yl)-piperidine-2,6-dione.
MX369806B (en) Indolone compounds and their use as ampa receptor modulators.
HK1260967A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
HK1261847A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
EA201892724A1 (en) TETRAHYDROPYRIDO [3,4-b] INDOL MODELERS OF ESTROGEN RECEPTORS AND THEIR APPLICATION